Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of over RMB 3 billion (approximately $433 million), representing a 46% year-over-year increase [25] - The company reported a full-year GAAP net income of RMB 436 million (approximately $62 million), marking the industry's first full-year GAAP profitability [5][28] - Operating cash flow was positive at RMB 117 million (approximately $17 million), marking the third consecutive year of positive operating cash flow [29] Business Line Data and Key Metrics Changes - Total shipments exceeded 1.6 million units, more than tripling from the previous year, including nearly 240,000 units from robotics LiDAR [25] - The company secured 2,026 design wins with key partners, including major automotive brands, reinforcing its position in the ADAS market [8] - The revamped ATX LiDAR features up to 256 channels, enhancing performance and reliability, with an order backlog exceeding 6 million units [10] Market Data and Key Metrics Changes - The company raised its 2026 LiDAR shipment outlook to between 3 million and 3.5 million units, reflecting strong demand across various applications [7] - The company achieved 100% LiDAR adoption on best-selling models from partners, marking a shift in LiDAR from a premium add-on to a core safety feature [8] - The company is positioned as the largest robotaxi LiDAR supplier globally, with significant partnerships across North America, Asia, and Europe [37] Company Strategy and Development Direction - The company aims to become a key enabler of physical AI, digitizing the real world and redefining human-robot interactions [23][51] - The company plans to launch two groundbreaking products targeting massive markets, enhancing perception and motion control for robots and autonomous systems [22][74] - The partnership with NVIDIA positions the company as a primary LiDAR partner for NVIDIA's DRIVE Hyperion 10 platform, facilitating global expansion [13][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining a strong growth trajectory in 2026, driven by robust demand for LiDAR in both passenger vehicles and robotics [58] - The company anticipates a modest mid-teen increase in operating expenses due to investments in new products, while managing other expenses effectively [97] - Management highlighted the importance of AI in enhancing operational efficiency and driving profitability [95] Other Important Information - The company has achieved significant manufacturing leverage, capturing over 40% of ADAS long-range LiDAR demand [9] - The company is the only Asian LiDAR manufacturer with German VDA 6.3 process audit certification, ensuring high production and quality standards [15] Q&A Session Summary Question: Details on Robotics Business Verticals - Management highlighted significant opportunities in humanoid and quadrupedal robotics, robotaxis, robovans, and robotic lawn mowers, with expectations for substantial growth in these segments [33][35][39] Question: Relationship with Sharpa - Management clarified that Hesai and Sharpa are independent entities, with potential for future collaborations but no current operational ties [48][51] Question: First Quarter Revenue Guidance - Management provided guidance for Q1 2026 revenues between RMB 650 million and RMB 700 million, with expected shipments of 400,000 to 450,000 LiDAR units [57][58] Question: ASP and Cost Reduction Outlook - Management discussed the expected decline in blended ASP due to product mix and outlined methods for further cost reduction, including scale and proprietary technology [89][90] Question: Operating Expenses Outlook - Management anticipates a modest increase in operating expenses for 2026, primarily due to investments in new products, while maintaining discipline in other areas [94][97]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of over CNY 3 billion (approximately $433 million), representing a 46% year-over-year increase [22] - The company reported a full-year GAAP net income of CNY 436 million (approximately $62 million), marking the industry's first full-year profitability [5][24] - Operating cash flow was positive at CNY 117 million (approximately $17 million), marking the third consecutive year of positive operating cash flow [25] - Gross margin remained healthy at over 40%, while operating expenses decreased by CNY 88 million (approximately $13 million) despite substantial revenue growth [23][24] Business Line Data and Key Metrics Changes - Total shipments exceeded 1.6 million units, more than tripling from the previous year, including nearly 240,000 units from robotics lidar [22] - The company raised its 2026 lidar shipment outlook to between 3 and 3.5 million units, reflecting significant scalability and resilience [6][25] - The ADAS lidar market share reached over 40%, with the company securing 2,026 design wins with key partners [7][8] Market Data and Key Metrics Changes - The company achieved 100% lidar adoption on best-selling models from partners, including Li Auto and Xiaomi, and entered the sub-CNY 100,000 price segment with Leapmotor [6][7] - The regulatory environment in China has reached a pivotal point, with Level 3 models now approved for public road deployment in cities like Beijing and Chongqing [9][10] - The company has secured ADAS orders from all top 10 OEMs in China and design wins with 40 automotive brands across more than 160 vehicle models [8] Company Strategy and Development Direction - The company aims to become a key enabler of physical AI, digitizing the real world and redefining how humans and robotics perceive and act [18][62] - The launch of two groundbreaking products targeting massive markets is anticipated, with initial revenue contributions expected as early as 2026 [19][62] - The partnership with Nvidia positions the company as a primary lidar partner for the DRIVE Hyperion 10 platform, facilitating a scalable turnkey model for global expansion [11][12] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a pivotal year for the evolution of intelligence, with expectations for significant growth in both lidar and robotics markets [14][19] - The company anticipates strong demand for lidar in both passenger vehicles and robotics, driving meaningful revenue increases in 2026 [49] - Management expressed confidence in maintaining a healthy financial profile and achieving sustainable profitability as the company scales [25][49] Other Important Information - The company has been recognized as the number one player across multiple major robotic lidar submarkets, including humanoid and quadruped robots [15][31] - The company is the only Asian lidar manufacturer with German VDA 6.3 process audit certification, ensuring adherence to rigorous production and quality standards [12] Q&A Session Summary Question: Can management provide more details about the robotics business verticals? - Management highlighted significant opportunities in humanoid and quadrupedal robotics, robotaxis, robovans, and robotic lawn mowers, with expectations for substantial growth in these segments [29][30][31] Question: What is the relationship between Hesai and Sharpa? - Management clarified that Hesai and Sharpa are independent entities, with potential for future collaborations but no operational control or equity relationship [39][40] Question: What is the first quarter revenue guidance and margin outlook? - The company expects first-quarter revenues between CNY 650 million and CNY 700 million, with total shipments anticipated to be in the range of 400,000 to 450,000 lidar units [46][48] Question: Will the company provide full-year net income guidance for 2026? - Management decided not to provide specific full-year net income guidance for 2026 but expressed confidence in maintaining growth in revenues, shipments, and profits [55][56] Question: What is the master plan behind the new non-auto, non-lidar products? - The company aims to empower robotics and elevate lives, with plans to launch two new products targeting massive markets, enhancing perception and motion control for robots [60][62]

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Fourth Quarter Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, with a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [7][8] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin at 93% [23][24] - Operating income for Q4 was $1.1 million, down from $2.3 million last year, primarily due to a non-cash impairment charge [24][25] Business Lines and Market Data - The company focused on three key commercial initiatives: strengthening relationships with independent distributors, selling into new healthcare facilities, and expanding within existing facilities [8][10] - The distributor network grew to over 450 contracted distributors by the end of 2025, up from over 350 in 2024 [9] - The company successfully sold into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Strategic Direction and Industry Competition - The company is transitioning to a pure-play surgical company, focusing exclusively on the surgical market and ceasing operations of the Tissue Health Plus segment [12][21] - The strategic priorities for 2026 include penetrating the surgical wound market, targeted investments in the surgical product portfolio, and bringing the OsStic product to market [31][34] - The company aims to leverage its differentiated products to address a multi-billion-dollar annual opportunity in the surgical market [30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as it enters 2026, emphasizing the strength of its commercial model and the potential for continued growth [30][31] - The company anticipates net revenue for 2026 to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025 [27][29] - Management highlighted the importance of clinical evidence and economic studies in supporting product growth and reimbursement opportunities [39][40] Other Important Information - The company secured an Innovative Technology contract from Vizient for its BIASURGE product, providing access to approximately 1,800 healthcare facilities [15] - Significant progress was made in expanding the intellectual property portfolio, with multiple patent applications submitted [18] - The company is on track to introduce the OsStic synthetic injectable bone bioadhesive to the U.S. market in Q1 2027 [19][20] Q&A Session Summary Question: Growth attribution to the Vizient contract for BIASURGE - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [37][38] Question: Impact of new studies on CellerateRX growth - Management emphasized the importance of clinical and economic evidence for CellerateRX, stating that it strengthens relationships with hospitals and is expected to positively impact future numbers [39][41]

Financial Performance - The company achieved net revenue of $103.1 million for the full year 2025, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - Adjusted EBITDA improved by 86% to $17 million for the full year 2025, and cash provided by operations was $6.8 million compared to cash used in operations of $24,000 in 2024 [5][26] Quarterly Performance - In Q4 2025, net revenue was $27.5 million, representing a 5% year-over-year growth, and a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [6][8] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin at 93% [23][24] - Operating income for Q4 was $1.1 million, down from $2.3 million last year, but increased to $2.9 million when excluding a non-cash impairment charge [24][25] Business Lines and Market Data - The growth in net revenue was primarily driven by sales of soft tissue products, with modest contributions from bone fusion products [6][8] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating a significant expansion of its distributor network [9] - The company achieved its target of selling into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Company Strategy and Industry Competition - The company is focused on the surgical market, having ceased operations of the Tissue Health Plus segment, and aims to be a leaner, pure-play surgical company [12][13] - Strategic priorities for 2026 include penetrating the surgical wound market, investing in the field sales team, and enhancing R&D initiatives [32][33] - The company is preparing for the U.S. commercialization of OsStic, a synthetic injectable bone bioadhesive, expected in Q1 2027, which is anticipated to be a significant addition to its product portfolio [19][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as a focused surgical company with a strong commercial model and significant growth opportunities in the surgical market [31][36] - The company reaffirmed its full year 2026 net revenue guidance of $116 million to $121 million, representing a growth of approximately 13% to 17% compared to 2025 [27][30] Other Important Information - The company has made progress in expanding its intellectual property portfolio, converting 11 provisional patent applications into non-provisional filings [18] - Clinical studies supporting the efficacy of BIASURGE and ALLOCYTE Plus were highlighted, showcasing their effectiveness in preventing surgical site infections and promoting bone healing [16][17] Q&A Session Summary Question: Impact of Vizient contract on growth - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [39][40] Question: CellerateRX growth and reimbursement - Management emphasized the importance of clinical evidence for CellerateRX and expressed confidence that the economic study would enhance relationships with hospitals and positively impact future numbers [41][42]

Financial Data and Key Metrics Changes - Total revenue reached nearly $4.6 billion, increasing 7.2% compared to 2024, marking record revenue for the third consecutive year [4][22] - Adjusted revenue growth, excluding foreign exchange and commodity impacts, was 6.9% year-over-year, outperforming the market by approximately 320 basis points [22][25] - EBITDA grew 11.2% year-over-year, with margins expanding by 40 basis points to 10.3% [22][28] - Net profit attributable to equity holders was $102 million, or 2.2% of revenue, compared to $62 million in 2024 [22][24] - Free cash flow was $124 million in 2025, down from $166 million in 2024 [22][32] Business Line Data and Key Metrics Changes - Successfully launched 57 customer programs, with 42 being new or conquest wins, and 36 for electric vehicle platforms [5][6] - New business bookings totaled $4.9 billion, including significant steer-by-wire wins with two leading Chinese NEV OEMs [10][13] - APAC revenue reached approximately $1.5 billion, representing a 9.8% increase year-over-year [5][26] Market Data and Key Metrics Changes - North America revenue increased by 4.4% year-over-year, while APAC led with 10.2% growth [26][27] - EMEA SA revenue increased by 8.5% year-over-year, supported by program ramp-ups [26][27] - North America remains the largest region at 50% of total revenue, followed by APAC at 32% and EMEA/SA at 17% [27] Company Strategy and Development Direction - Focus on long-term profitable growth through new business wins and program launches [4][6] - Emphasis on expanding the motion-by-wire product portfolio, including steer-by-wire and electromechanical braking systems [10][20] - Strategic partnerships with OEMs aligned with industry megatrends such as electrification and autonomy [14][15] Management's Comments on Operating Environment and Future Outlook - Management expects above-market revenue growth in 2026 of approximately 200-300 basis points, driven primarily by continued growth in APAC [34] - Anticipated margin expansion due to net performance improvements and increased volume leverage [34] - Ongoing geopolitical risks are acknowledged, with management actively managing these through engagement with customers and suppliers [34] Other Important Information - The board approved a $46 million dividend, representing a 45% payout ratio, up from 35% in 2024 [6][22] - The company opened new manufacturing facilities in Thailand and expanded existing facilities in China and India to support growth [17][18] Q&A Session Summary Question: Long-term focus on steer-by-wire or integrated solutions? - Management indicated a focus on becoming a chassis motion-by-wire supplier, with the development of electromechanical braking as a critical milestone [40][41] Question: Expectations for customer compensation related to impairments? - Management expects to recover costs related to program cancellations in 2026, with $24 million of impairments recorded in 2025 [44][46] Question: Estimated revenue growth and EBITDA margin by area for 2026? - Management anticipates revenue growth above market by 200-300 basis points, with EBITDA margins in APAC expected to maintain around 16%-17% [50][51]

Financial Data and Key Metrics Changes - NRx Pharmaceuticals reduced its loss from operations by approximately $2.3 million to $16.2 million for the year ended December 31, 2025, compared to $18.5 million for 2024, primarily due to a decrease in research and development expenses [20] - Research and development expenses decreased by approximately $2.4 million to $3.8 million for the year ended December 31, 2025, compared to $6.2 million for 2024 [20] - General and administrative expenses decreased by approximately $0.4 million to $13.1 million for the year ended December 31, 2025, compared to $13.5 million for 2024 [21] - As of December 31, 2025, the company had approximately $7.8 million in cash and cash equivalents, which is expected to support operations through the end of 2026 [21] Business Line Data and Key Metrics Changes - The HOPE Therapeutics subsidiary demonstrated EBITDA positive revenue growth, with the company anticipating pro forma profitability by the end of 2026 [3][4] - The company has manufactured three registration batches of KETAFREE in anticipation of FDA approval, with plans to have 200,000 units in the warehouse at the time of generic approval [26] - The NRX-101 program is being developed for a broader application, with a market estimate exceeding $1 billion for its newly validated indication [14] Market Data and Key Metrics Changes - The existing market for ketamine is projected at approximately $750 million annually, with KETAFREE expected to offer a superior option due to its preservative-free formulation [6] - The addressable population for NRX-100, if approved for a broader treatment-resistant depression label, could expand to approximately 12 million patients [34] Company Strategy and Development Direction - The company aims to become a fully commercial pharmaceutical entity by 2026, with a focus on advancing primary drug development initiatives and planned clinic acquisitions [21] - NRx Pharmaceuticals is pursuing an innovative new drug application for NRX-100 under FDA Fast Track designation, with a potential decision date by the end of 2026 or early 2027 [9][10] - The company is collaborating with neurocare group AG to integrate pharmaceutical and medical device development for enhanced patient care in neuroplastic psychiatry [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the potential for drug approvals and the transformative changes within the company, highlighting the importance of their clinical network and revenue generation [3][4][45] - The management believes that the current available cash resources, along with anticipated growth in clinic revenue, will be sufficient to support ongoing operations [21] Other Important Information - The FDA has granted an expanded Fast Track designation for NRX-100, which now includes all patients with suicidal ideation and depression, significantly broadening its potential market [10] - The company has launched a nationwide expanded access program for NRX-101, allowing physicians to access the medication at no charge to patients while awaiting a confirmatory phase III trial [14] Q&A Session Summary Question: Update on KETAFREE inventory and market pricing - The company has already manufactured three registration batches and anticipates having 200,000 units ready at the time of generic approval [25][26] - The potential impact of being the only preservative-free ketamine on pricing models is acknowledged, with market demand likely influencing pricing [27] Question: Clinical data for extended release D-cycloserine - The company believes that continued exposure to D-cycloserine is important for neuroplastic effects, and further in vitro work is planned [28] Question: Type C meeting with the FDA regarding NRX-100 - The FDA indicated that existing clinical trials data and real-world evidence could be reviewed without the need for additional clinical trials [32] - The addressable population for treatment-resistant depression is significantly larger than initially anticipated, which could positively impact payer coverage [34][36] Question: Commercial strategy for ANDA approval - The company plans to target both hospital surgery centers and psychiatric clinics for the commercialization of KETAFREE, with a focus on establishing a medical liaison service [40][41]

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $365.3 million, representing a 4.7% year-over-year growth, primarily driven by double-digit international expansion, particularly in APAC, which grew by 26.9% [5][14] - Gross profit for 2025 was $215.1 million, with a gross margin of 58.9%, down from 62.1% in 2024, attributed to shifts in geographic and product mix and new import tariffs [17] - Adjusted net profit for 2025 was $31 million, up 7.9% year-on-year, with an adjusted net profit margin of 8.5%, reflecting disciplined cost management and efficiency gains [17] Business Line Data and Key Metrics Changes - Energy-based devices (EBD) revenue was $310.4 million, representing 85% of total revenue, essentially flat year-on-year, supported by strong demand for Alma Harmony and Alma Hybrid platforms [14][15] - Injectable revenues reached $28 million, up 185.6% year-on-year, reflecting significant diversification due to Profhilo's momentum and broader adoption by practitioners [15] Market Data and Key Metrics Changes - North America revenue was $111 million, down 19.2% year-on-year, impacted by weakened macroeconomic conditions and softer consumer demand [14] - International markets, excluding North America, grew 20.1%, led by Asia-Pacific, which rose 26.9% year-on-year, serving as the primary growth engine [14] Company Strategy and Development Direction - The company is focused on building a broader ecosystem that integrates technologies, diagnostics, injectables, and digital capabilities to adapt to evolving market demands [3][4] - Plans for 2026 include strengthening the flagship device portfolio, expanding the global energy-based device offering, and introducing additional EBD solutions in Thailand [7][10] - The company aims to capture long-term growth opportunities in the global medical aesthetics market while maintaining operational discipline in North America [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the new executive team and their ability to lead the company with a focus on execution, operational discipline, and long-term value creation [4] - The company anticipates a recovery in the U.S. market in 2026, contingent on improvements in macroeconomic conditions and interest rates [49] Other Important Information - The company completed a structured leadership transition and is committed to balancing reinvestment for sustainable growth with shareholder value retention [4][17] - R&D spending was $16.9 million in 2025, reflecting ongoing investments in clinical programs and next-generation products [16] Q&A Session Summary Question: What specific measures are being taken to cut down the sales and marketing expense ratio? - Management indicated that proactive measures were taken to drive efficiency, resulting in reductions in sales and marketing expenses while still investing in strategic projects like DAXXIFY [20][21] Question: Can you provide an update on the company's R&D pipeline and expected clinical progress? - The company plans several launches in 2026, particularly in the hair growth segment, and is also assessing additional products for future opportunities [24][25] Question: What is the sales strategy for energy-based devices in China for 2026? - The company aims to maintain its dominant position in China and leverage synergies across different business segments to drive growth [28][29] Question: What are the plans for the commercialization of DAXXIFY this year? - The company has a capacity of 100,000 units for DAXXIFY and plans to target high-value clinics initially, with positive feedback received so far [34][35] Question: What is the strategic roadmap for 2026 and key growth drivers? - The strategy focuses on creating an ecosystem to provide more value to practitioners and enhance brand strength, with a strong emphasis on energy-based devices and hair growth solutions [38][40] Question: What are the underlying reasons for the softness in the U.S. segment and the potential for recovery? - Management noted that the decline was primarily due to macroeconomic conditions, but they are optimistic about recovery in 2026 with improved economic indicators [46][49] Question: What is the progress on AI-enabled products and the impact of geopolitical issues? - The company is leveraging partnerships for AI technologies and has maintained operational capacity despite geopolitical challenges, although there are impacts on shipping costs [56][58]

Financial Data and Key Metrics Changes - In Q4 2025, total revenues reached $63 million, reflecting a 9% year-over-year growth, marking a turnaround from previous quarters [8] - Gross profit for Q4 was $39 million, up 16% year-over-year, with gross margin improving to 63% from 59% [8] - Full year 2025 total revenues decreased 12% year-over-year to $224 million, but gross margin increased to 65% from 60%, the highest since going public in 2013 [10] Business Line Data and Key Metrics Changes - The branded apparel business grew over 143% in 2025, accounting for 17% of total revenue, up from 6% in 2024 [6] - The introduction of higher margin proprietary product lines contributed significantly to gross margin expansion [10] Market Data and Key Metrics Changes - The company has successfully navigated a challenging e-commerce environment, achieving a positive revenue growth in Q4 after several quarters of decline [4][10] - The focus on consumer lifestyle products has allowed the company to command premium pricing, enhancing overall profitability [5] Company Strategy and Development Direction - The company is transforming into a global consumer lifestyle company, focusing on festivals, holidays, and special occasions with customized products [5] - A brand matrix strategy has been adopted, launching three proprietary apparel brands since 2024, targeting women aged 30 and above [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering overall revenue and profit growth in 2026, following a successful turnaround in 2025 [7][15] - The company has embraced AI to enhance operational efficiency and marketing strategies, contributing to improved profit margins [6] Other Important Information - The company achieved a net income of $8.3 million in 2025, a significant turnaround from a loss of $2.5 million in 2024 [11] - Positive operating cash flow of $6.2 million was generated in 2025, indicating improved financial health [11] Q&A Session Summary Question: Will next year be a growth year? - Management is confident that 2026 will deliver another year of growth in both profit and revenues, although official guidance has not yet been provided [15] Question: What is the shareholder base composition? - Insiders and directors hold roughly 70% of the shares, with about 30% in public float, totaling approximately 18 million ADS [17]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of over CNY 3 billion (approximately $433 million), representing a 46% year-over-year increase [20] - The company reported a full-year GAAP net income of CNY 436 million (approximately $62 million), marking the industry's first full-year GAAP profitability [22] - Operating cash flow was positive at CNY 117 million (approximately $17 million), marking the third consecutive year of positive operating cash flow [23] Business Line Data and Key Metrics Changes - Total shipments exceeded 1.6 million units, more than tripling from the previous year, including nearly 240,000 units from robotics lidar [20] - The ADAS lidar market share reached over 40%, with the flagship ATX lidar contributing significantly to this position [4][6] - The company secured 2,026 design wins with key partners, including major automotive brands, reinforcing its leadership in the ADAS market [6] Market Data and Key Metrics Changes - The company is raising its 2026 lidar shipment outlook to between 3 and 3.5 million units, reflecting strong demand across various applications [5] - The regulatory environment in China has reached a pivotal point, with Level 3 models now approved for public road deployment, increasing the demand for lidar systems [8] Company Strategy and Development Direction - The company aims to become a key enabler of physical AI, digitizing the real world and redefining how humans and robotics perceive and act [18] - A strategic partnership with Grab in Southeast Asia is expected to enhance the company's footprint in the region [10] - The company plans to launch two groundbreaking products targeting massive markets, which are expected to become a second growth engine [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining a strong growth trajectory in 2026, driven by robust demand for lidar in both passenger vehicles and robotics [48] - The company anticipates that the commercialization of new products will begin contributing to revenue as early as 2026 [62] - Management emphasized the importance of AI in enhancing operational efficiency and driving profitability [81] Other Important Information - The company achieved a gross margin of over 40% while reducing operating expenses by CNY 88 million (approximately $13 million) despite substantial revenue growth [21][22] - The company is the only Asian lidar manufacturer with German VDA 6.3 process audit certification, indicating high production and quality standards [11] Q&A Session Summary Question: Can management provide more details about the robotics business and its different verticals? - Management highlighted that the robotics business is blooming, with significant opportunities in humanoid and quadrupedal robots, robotaxis, and robovans, expecting annual shipments in these segments to reach five-digit levels in 2026 [28][29] Question: What is the relationship between Hesai and Sharpa, and are there opportunities for collaboration? - Management clarified that Hesai and Sharpa are independent entities, with potential for future collaborations where it makes strategic sense, but emphasized that their primary focus remains on Hesai [39][41] Question: What is the outlook for ASP and methods for cost reduction? - Management indicated that ASP declines are primarily driven by product mix rather than price, and outlined strategies for further cost reduction through scale, proprietary technology, and automated manufacturing [76][77] Question: What is the outlook for operating expenses in 2026? - Management expects a modest mid-teen increase in overall operating expenses, primarily due to investments in new products, while excluding new business spend, operating expenses are expected to remain flat or decrease [82]

Financial Performance - For the full year 2025, the company achieved net revenue of $103.1 million, marking a 19% year-over-year growth and exceeding $100 million for the first time in its history [4] - Gross margins expanded by approximately 200 basis points to 93% for the full year 2025, with a significant reduction in net loss from continuing operations by 80% to $1.5 million [5] - The company generated $6.8 million of cash from operations in 2025, a substantial improvement from $24,000 used in operations in 2024 [5][25] Quarterly Performance - In Q4 2025, net revenue was $27.5 million, reflecting a 5% year-over-year growth, and a 13% increase when excluding $1.8 million of BIASURGE sales from Q4 2024 [6][7] - Gross profit for Q4 increased by $1.6 million or 7% to $25.7 million, with gross margin rising to 93% [22][23] - Adjusted EBITDA for Q4 was $4.7 million, compared to $4.1 million in the previous year [24] Business Lines and Market Data - The growth in net revenue was primarily driven by sales of soft tissue products, with contributions from bone fusion products [6] - The company ended 2025 with over 450 contracted distributors, up from over 350 at the end of 2024, indicating a significant expansion of its distributor network [9] - The company achieved its target of selling into over 1,450 healthcare facilities by the end of 2025, compared to over 1,300 in 2024 [10] Strategic Direction and Industry Competition - The company is focusing exclusively on the surgical market, having ceased operations in the Tissue Health Plus segment, which is now classified as discontinued operations [12][13] - The strategic priorities for 2026 include penetrating the surgical wound market, investing in the sales team and R&D, and bringing the OsStic product to market [31][34] - The company aims to leverage its differentiated products to address a multi-billion-dollar annual opportunity in the surgical market [30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning as a focused surgical company, emphasizing the importance of clinical evidence and economic studies to support product adoption [39][40] - The company anticipates net revenue for 2026 to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to 2025 [26][29] Other Important Information - The company secured an Innovative Technology contract from Vizient for its BIASURGE product, which will provide access to approximately 1,800 healthcare facilities [15] - The R&D team is focused on expanding the IP portfolio and has converted 11 provisional patent applications into non-provisional filings [18] Q&A Session Summary Question: Growth attribution to the Vizient contract for BIASURGE - Management acknowledged the significance of the Vizient contract and indicated that it would take time to educate facilities, but it provides a strong growth runway for 2026 and beyond [37][38] Question: Impact of cost-effectiveness studies on CellerateRX growth - Management emphasized the importance of clinical and economic evidence for CellerateRX, stating that it strengthens relationships within hospitals and is expected to positively impact future numbers [39][40]